All data are based on the daily closing price as of July 18, 2024
g

Genexine

095700.KQ
5.03 USD
-0.07
-1.37%

Overview

Last close
5.03 usd
Market cap
208.66M usd
52 week high
12.21 usd
52 week low
4.49 usd
Target price
88.06 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
68.9172
Price/Book Value
1.0285
Enterprise Value
222.45M usd
EV/Revenue
69.5824
EV/EBITDA
-5.3366

Key financials

Revenue TTM
4.20M usd
Gross Profit TTM
8.14M usd
EBITDA TTM
-27.58M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
271.39M usd
Net debt
N/A usd

About

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes. The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.
  • Symbol
    095700.KQ
  • Exchange
    KQ
  • Isin
    KR7095700001
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://www.genexine.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top